(Press-News.org) Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery.
At the annual meeting for the American Society of Clinical Oncology, the nation's premier association of clinical oncologists, Harry D. Bear, M.D., Ph.D., Chair, Division of Surgical Oncology at Virginia Commonwealth University Massey Cancer Center, presented the Avastin findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-40 clinical trial. Bear, who served as the trial's protocol chair, explained that Avastin, when added to preoperative chemotherapy regimens, increased toxicity but also increased pathologic complete response rates by more than 6 percent (34.5 percent versus 28.4 percent) and clinical complete response rates by approximately 8 percent (64.3 percent versus 55.8 percent). Pathologic complete response was defined in the study as no remaining invasive cancer left in the breast, and clinical complete response was defined as a complete disappearance of cancer with no evidence of disease progression. Patients with hormone receptor positive breast cancers appeared to benefit most from the treatment.
"While encouraging, the results of this study will probably not affect standard neoadjuvant or adjuvant chemotherapy practices in the near term," says Bear. "There are many different types of breast cancer, and we need more definitive biological predictors of response in order to more accurately identify the patients who will benefit most from Avastin."
Though hormone receptor positive patients benefited most from the addition of Avastin in the NSABP Protocol B-40 trial, a second study presented during the same session at the ASCO meeting seemed to contradict the findings. The second study, known as GeparQuinto, was conducted in Germany and found that Avastin benefitted patients with triple negative cancers, but not patients with hormone receptor positive cancers.
"The more we understand tumor biology, the more personalized cancer care becomes. By identifying the factors that made Avastin beneficial, we can hopefully test future breast cancer patients to determine whether or not it should be included in their treatment," says Bear.
The NSABP Protocol B-40 trial included 1,206 patients with operable HER2-negative breast cancer and tested different preoperative, or "neoadjuvant," chemotherapy regimens. The trial had two objectives. The first was to determine whether adding the chemotherapy agents capecitabine or gemcitabine to the standard neoadjuvant chemotherapy regimen of docetaxel followed by a combination of doxorubicin and cyclophosphamide increased the pathologic complete response rate. The second objective was to test whether adding Avastin to chemotherapy before surgery increased the pathologic complete response rate. While the addition of Avastin did improve the pathologic complete response rate, the addition of the chemotherapy agents capecitabine and gemcitabine did not.
"We need more research focusing on patient biology and tumor differences to understand why Avastin works for some but not others. We hope to gain insight by analyzing tumor biopsies and blood samples from patients in the B-40 trial and other recent Avastin studies," says Bear. "In addition, since the patients who received Avastin preoperatively also received it after surgery, it is possible the drug may improve long-term outcomes. We will follow these patients for many years to come to determine whether Avastin increased cure rates."
###
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace at (804) 628-1550.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 66 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center: Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls more than 31,000 students in 211 certificate and degree programs in the arts, sciences and humanities. Sixty-nine of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
2011-08-25
ELSE PRESS RELEASES FROM THIS DATE:
Study: Afghan patients a common source of drug-resistant bacteria
2011-08-25
Afghan patients treated at a U.S. military hospital in Afghanistan often carry multidrug-resistant (MDR) bacteria, according to a report in the September issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. The findings underscore the need for effective infection control measures at deployed hospitals where both soldiers and local patients are treated, the study's authors say.
The research team, led by Air Force Lieutenant Colonel Deena Sutter of the San Antonio Military Medical Center, studied U.S. ...
Children's hospitals not equipped to handle pandemics
2011-08-25
AURORA, Colo. (Aug. 23, 2011) – A new study of children's hospitals nationwide has found them underequipped to handle a major surge of patients in the event of a pandemic, and urges health care institutions and government agencies to immediately review emergency preparedness plans as flu season approaches.
"Every year we get lucky," said the study's lead author, Marion Sills, MD, MPH, and associate professor of pediatrics at the University of Colorado School of Medicine. "But it wouldn't take much of an epidemic to put us over capacity. If that happens where do the children ...
When erectile dysfunction isn't whole story
2011-08-25
NEW YORK (Aug. 23, 2011) -- For men with erectile dysfunction (ED), 65 percent are unable to have an orgasm and 58 percent have problems with ejaculation, according to new research led by physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.
The study followed 12,130 men with mild to severe ED and is the largest-ever analysis of orgasmic and ejaculatory dysfunction. Results are published in today's edition of the British Journal of Urology International.
Approximately 30 million American men, or half of all men aged 40 to 70, have trouble ...
A better test for a potato pest
2011-08-25
This press release is available in Spanish.
A U.S. Department of Agriculture (USDA) scientist has created a new weapon in the war being waged against the potato cyst nematode-a diagnostic test that identifies the type of nematode infesting a grower's field.
Xiaohong Wang, a molecular biologist with the Agricultural Research Service (ARS) Robert W. Holley Center for Agriculture and Health in Ithaca, N.Y., has filed a patent application on the monitoring tool, developed in part by cloning and sequencing key genes. ARS is USDA's principal intramural scientific research ...
Ancient whale skulls and directional hearing: A twisted tale
2011-08-25
Skewed skulls may have helped early whales find the direction of sounds in water and are not solely, as previously thought, a later adaptation related to echolocation.
Scientists affiliated with the University of Michigan and funded by the National Science Foundation (NSF) report the finding in a paper published online this week in the journal Proceedings of the National Academy of Sciences.
Asymmetric skulls are a well-known characteristic of the modern whale group known as "odontocetes" or toothed whales.
These whales also have highly modified nasal structures with ...
Fine art in advertising can backfire
2011-08-25
CHESTNUT HILL, MA (August 23, 2011) – Throughout the ages, fine art has been accorded a special significance and recognized as a powerful communication tool. Art has been used to sell everything from products to politics to religion.
But art can be stripped of its special status if used carelessly by advertisers, according to a new study by researchers from Boston College and the University of Houston.
If the artwork is viewed as a product-relevant illustration, then consumers no longer view it as art. Suddenly, they can take a critical view of its message, according ...
U of T research shows anti-aging techniques not yet viewed as acceptable
2011-08-25
Studies from the University of Toronto's psychology department show that people who use more invasive anti-aging methods such as Botox injections or surgery are viewed more negatively than those who use milder techniques such as sun-avoidance and facial creams and younger adults are more negative about using anti-aging methods than older adults.
"These results suggest that despite the rapid growth of the anti-aging cosmetic industry, age concealment has not yet become universally accepted," said lead author and associate professor, Alison Chasteen. "This is important ...
Decision making changes with age -- and age helps!
2011-08-25
We make decisions all our lives—so you'd think we'd get better and better at it. Yet research has shown that younger adults are better decision makers than older ones. Some Texas psychologists, puzzled by these findings, suspected the experiments were biased toward younger brains.
So, rather than testing the ability to make decisions one at a time without regard to past or future, as earlier research did, these psychologists designed a model requiring participants to evaluate each result in order to strategize the next choice, more like decision making in the real world.
The ...
Safetyshop Announces Launch of Online News Feed
2011-08-25
Safetyshop, the UK's leading safety equipment manufacturer, has launched an industry news feed on the homepage of its website.
Designed to be a useful resource for regular customers and new visitors alike, the latest news section contains stories which relate to all aspects of health and safety, from new legislation and prosecutions brought by the Health and Safety Executive, to road safety initiatives and changes affecting first aid kits in the workplace. The feed is updated on a daily basis to ensure breaking news makes it onto the site as quickly as possible.
The ...
Economic inequality is linked to biased self-perception
2011-08-25
Pretty much everybody thinks they're better than average. But in some cultures, people are more self-aggrandizing than in others. Until now, national differences in "self-enhancement" have been chalked up to an East-West individualism-versus-collectivism divide. In the West, where people value independence, personal success, and uniqueness, psychologists have said, self-inflation is more rampant. In the East, where interdependence, harmony, and belonging are valued, modesty prevails.
Now an analysis of data gathered from 1,625 people in 15 culturally diverse countries ...